EGFR L858R

Clinical trials for EGFR L858R explained in plain language.

Never miss a new study

Get alerted when new EGFR L858R trials appear

Sign up with your email to follow new studies for EGFR L858R, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Completed 1

New drug combo shows promise for Hard-to-Treat lung cancer

Disease control Completed

This study tested a combination of two drugs—bevacizumab and a higher dose of icotinib—in 35 adults with advanced non-squamous lung cancer that has a specific genetic mutation (EGFR L858R). The goal was to see if the combo could control the cancer longer than standard treatment. …

Matched conditions: EGFR L858R

Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control

Last updated May 17, 2026 04:29 UTC

EGFR L858R

Get alerted when new EGFR L858R trials appear

New drug combo shows promise for Hard-to-Treat lung cancer